Tissue Regenix Group (LSE:TRX) Other Stockholders Equity: £15.63 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Tissue Regenix Group Other Stockholders Equity?

Tissue Regenix Group LSE:TRX Other Stockholders Equity is £15.63 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Tissue Regenix Group's Other Stockholders Equity for the quarter that ended in Jun. 2025 was £15.63 Mil.

Tissue Regenix Group's quarterly Other Stockholders Equity increased from Jun. 2024 (£16.12 Mil) to Dec. 2024 (£16.39 Mil) but then declined from Dec. 2024 (£16.39 Mil) to Jun. 2025 (£15.63 Mil).

Tissue Regenix Group's annual Other Stockholders Equity increased from Dec. 2022 (£9.27 Mil) to Dec. 2023 (£16.45 Mil) but then declined from Dec. 2023 (£16.45 Mil) to Dec. 2024 (£16.39 Mil).

Tissue Regenix Group Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Other Stockholders Equity Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.37 9.55 9.27 16.45 16.39

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.36 16.45 16.12 16.39 15.63

Tissue Regenix Group Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of £15.63 Mil mean?
Tissue Regenix Group (LSE:TRX) has a Other Stockholders Equity of £15.63 Mil as of Jun. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Other Stockholders Equity too high?
Tissue Regenix Group's current Other Stockholders Equity is £15.63 Mil.
How does Tissue Regenix Group's Other Stockholders Equity compare to VRTX and REGN?
Tissue Regenix Group's Other Stockholders Equity of £15.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current Other Stockholders Equity is £15.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current Other Stockholders Equity of £15.63 Mil. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current Other Stockholders Equity is £15.63 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current Other Stockholders Equity is £15.63 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.